Horizon Therapeutics Public Limited (NASDAQ:HZNP) Given Consensus Rating of “Hold” by Brokerages

Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) has earned an average rating of “Hold” from the fourteen analysts that are currently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $111.00.

A number of equities research analysts have weighed in on the company. StockNews.com upgraded Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. BMO Capital Markets downgraded Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 13th. TheStreet upgraded Horizon Therapeutics Public from a “c+” rating to a “b-” rating in a research report on Tuesday, November 22nd. Stifel Nicolaus downgraded Horizon Therapeutics Public from a “buy” rating to a “hold” rating and cut their target price for the stock from $138.00 to $116.50 in a research report on Monday, December 12th. Finally, HC Wainwright initiated coverage on Horizon Therapeutics Public in a research report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price objective for the company.

Insider Buying and Selling at Horizon Therapeutics Public

In other Horizon Therapeutics Public news, EVP Jeffrey W. Sherman sold 28,352 shares of the business’s stock in a transaction on Monday, December 12th. The shares were sold at an average price of $111.45, for a total transaction of $3,159,830.40. Following the sale, the executive vice president now directly owns 54,501 shares of the company’s stock, valued at approximately $6,074,136.45. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP Jeffrey W. Sherman sold 28,352 shares of the company’s stock in a transaction on Monday, December 12th. The shares were sold at an average price of $111.45, for a total value of $3,159,830.40. Following the transaction, the executive vice president now directly owns 54,501 shares of the company’s stock, valued at $6,074,136.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jeffrey W. Sherman sold 5,187 shares of the stock in a transaction on Friday, January 6th. The stock was sold at an average price of $113.29, for a total transaction of $587,635.23. Following the transaction, the executive vice president now directly owns 49,314 shares in the company, valued at $5,586,783.06. The disclosure for this sale can be found here. Insiders have sold a total of 100,184 shares of company stock valued at $11,285,478 in the last three months. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of Horizon Therapeutics Public

Hedge funds have recently modified their holdings of the company. Samalin Investment Counsel LLC bought a new position in Horizon Therapeutics Public in the first quarter valued at approximately $41,000. CoreCap Advisors LLC acquired a new stake in shares of Horizon Therapeutics Public during the second quarter worth $33,000. Steward Financial Group LLC acquired a new stake in shares of Horizon Therapeutics Public during the second quarter worth $41,000. Allworth Financial LP raised its holdings in shares of Horizon Therapeutics Public by 936.7% during the third quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 562 shares during the period. Finally, CI Investments Inc. raised its holdings in shares of Horizon Therapeutics Public by 75.9% during the third quarter. CI Investments Inc. now owns 628 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 271 shares during the period. Institutional investors and hedge funds own 91.01% of the company’s stock.

Horizon Therapeutics Public Stock Performance

Shares of NASDAQ HZNP opened at $112.95 on Thursday. The company has a current ratio of 3.96, a quick ratio of 3.74 and a debt-to-equity ratio of 0.51. The stock has a 50 day simple moving average of $100.67 and a 200-day simple moving average of $79.91. The company has a market cap of $25.60 billion, a PE ratio of 46.29, a P/E/G ratio of 1.74 and a beta of 1.16. Horizon Therapeutics Public has a 12-month low of $57.84 and a 12-month high of $117.49.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.25. The business had revenue of $925.36 million during the quarter, compared to the consensus estimate of $888.93 million. Horizon Therapeutics Public had a return on equity of 24.59% and a net margin of 15.51%. On average, equities research analysts forecast that Horizon Therapeutics Public will post 4.23 EPS for the current year.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.